Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9369168 | 0.90 | MAPT (0.47) | HMGCRMAPTALDH1A1HTTLMNA | |
| SCHEMBL30662465 | 0.90 | MAPT (0.47) | HMGCRMAPTALDH1A1HTTLMNA | |
| SCHEMBL10595171 | 0.85 | MAPT (0.42) | HMGCRMAPTALDH1A1HTTLMNA | |
| SCHEMBL9838522 | 0.81 | KDM4E (0.44) | MAPTALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL6815278 | 0.81 | LMNA (0.56) | MAPTALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL31757016 | 0.81 | ALDH1A1 (0.51) | MAPTALDH1A1HTTLMNACYP3A4 | |
| SCHEMBL29195279 | 0.80 | LMNA (0.58) | MAPTALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL16388497 | 0.80 | ALDH1A1 (0.52) | MAPTALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL8876679 | 0.80 | ALDH1A1 (0.65) | MAPTALDH1A1HTTSMN1; SMN2NPC1 | |
| SCHEMBL6815164 | 0.78 | LMNA (0.60) | MAPTALDH1A1HTTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | disclosed |
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | disclosed |
| CN-113302183-A | Cyclic ureas | 圣瑞诺有限公司 | 2021-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292305-A1 | Cyclic Ureas | RIPK1, RIPK3, RIPK4 | HMGCR 3990/4885MAPT 3200/4885ALDH1A1 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.